Get the Stockscreener App
6.13
2.51%
0.15
Pre-market:
6.13
Agenus Inc stock is traded at $6.13, with a volume of 1.23M.
It is up +2.51% in the last 24 hours and up +102.31% over the past month.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
See More
Previous Close:
$5.98
Open:
$5.99
24h Volume:
1.23M
Relative Volume:
0.33
Market Cap:
$255.27M
Revenue:
$123.87M
Net Income/Loss:
$62.49M
P/E Ratio:
3.6718
EPS:
1.6695
Net Cash Flow:
$-87.53M
1W Performance:
+23.34%
1M Performance:
+102.31%
6M Performance:
+92.16%
1Y Performance:
+2.85%
1-Day Range:
$5.87
$6.20
1-Week Range:
$4.99
$6.23
52-Week Range:
$2.71
$8.70
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
6.13 | 255.27M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
AGEN|Agenus Inc|Price:6.135|Chg%:+0.155 - TradingKey
BlackRock (AGEN) discloses 2.51M-share, 6% stake in Agenus common stock - Stock Titan
Agenus Inc (AGEN) Balance Sheet - TradingKey
Agenus Inc (AGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Agenus Inc (AGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
AGEN|Agenus Inc|Price:5.980|Chg%:-0.210 - TradingKey
Agenus Inc (AGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Agenus Inc (AGEN) Cash Flow - TradingKey
Agenus Inc. Revenue Breakdown – NASDAQ:AGEN - TradingView
Agenus Inc. (Nasdaq: AGEN) Q2 2025 Earnings Call | 08/27/2025 Brett Kulak (luI2X2n2sY) - Mshale
AGEN Stock MASSIVE NEWS!? (Thank Me Later Bro) Agenus Stock Best Broker Review Bp (nGoDV3hD3d) - Mshale
Agenus Inc. (AGEN) stock price, news, quote and history - Yahoo Finance UK
Agenus Inc (AGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Agenus Inc - GuruFocus
Agenus Inc. (AGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Do Options Traders Know Something About Agenus Stock We Don't? - Yahoo Finance
Agenus: More Shares, Fresh Starts, And Executive Pay Under The Microscope Sportitalia (bXVgSS8OPp) - Mshale
Agenus Analysis: Strategic Pivot And Financing Valuation Report AGEN $AGEN #AGEN #stockmarket See No Evil Bafta (mAryLCXecM) - Mshale
Agenus Analysis: Strategic Pivot And Financing Valuation Report AGEN $AGEN #AGEN #stockmarket Incendio Montesilvano (bwWkwlpOZa) - Mshale
Agenus Will Present Three Neoajuvant Studies at ESMO26 - Oncodaily
RA Capital and affiliates (NASDAQ: AGEN) disclose 9.99% beneficial ownership in Agenus - Stock Titan
Agenus (AGEN) Registration filing Summary - Quartr
Agenus (NASDAQ: AGEN) registers 2.13M previously issued shares for resale - Stock Titan
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 - BioSpace
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026 - 뉴스와이어
Agenus Inc.AGEN Stock Chart Technical Analysis For 03-09-2020 Giro D'italia (XPKerZ1996) - Mshale
My Take On Agenus's Cash Burn & Legal Risk Keldon Johnson (KIhGnPaajk) - Mshale
Inside the ROBBIN Phase 3 Strategy: Bringing BOT+BAL Into the Neoadjuvant Setting - Oncodaily
Agenus Inc. (AGEN) investors disclose 4.53M-share stake capped at 9.99% - Stock Titan
Agenus Inc. (Nasdaq: AGEN) Q2 2025 Earnings Call | 08/27/2025 Vocm News (LGDv0nXjs0) - Mshale
Agenus abstracts on cancer drug combo accepted at ESMO 2026 - Investing.com
Agenus abstracts on cancer drug combo accepted at ESMO 2026 By Investing.com - Investing.com UK
🔴 Agenus Inc. AGEN Stock Trading Facts 🔴 Gianna Nannini (cYwfB9Crlv) - Mshale
Why Agenus (AGEN Stock) Just Rocketed Up—Buy Now Or Too Late? Grêmio Vs Flamengo (4gW3JuWkOx) - Mshale
A.G.E.N.U.S. 8-K: My Take On The C.F.I.U.S. Delay Ctv News Ottawa (HFy9tZJhiU) - Mshale
Insider Trading AGEN Agenus Inc 2021 05 18 Blowing Dust Advisory (ETsN3n1J0C) - Mshale
Agenus Inc. (Nasdaq: AGEN) Q2 2025 Earnings Call | 08/27/2025 La Casa De Papel (vN5Dv9DbRJ) - Mshale
Agenus (AGEN) Could Be 83% Undervalued On Phase 1b Data And $340 Million Raise - Sahm
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer - 뉴스와이어
Agenus Surges 83% On $340 Million Financing: The Road To A 2030 Breakthrough (NASDAQ:AGEN) - Seeking Alpha
Agenus stock doubles as biotech narrows Phase 3 bet - AOL.com
Form 4 Agenus Inc For: 14 July By Investing.com - Investing.com Nigeria
Agenus Inc. (NASDAQ: AGEN) director takes 4,852-share stock salary grant - Stock Titan
AGEN Stock Pulls Back After Huge Spike As Traders Dig Into Financials - StocksToTrade
Agenus Announces Up to $340M Financing to Advance Phase 3 ROBBIN Trial in MSS Colon Cancer - Oncodaily
Jennifer S. Buell: Agenus’ Next Chapter in Early Immuno-Oncology With Phase 3 ROBBIN Trial - Oncodaily
From “Most Promising” to Phase 3: Up to $340M to Advance BOT/BAL in MSS Colon Cancer - Oncodaily
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot - The Globe and Mail
Why Is Agenus Stock Falling on Tuesday? - Benzinga
Agenus Discontinues Phase 3 BATTMAN Trial in Metastatic MSS Colorectal Cancer - CancerNetwork
Zack Armen: A New Milestone for Agenus’ BOT+BAL Program in MSS Colon Cancer - Oncodaily
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):